Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Accepted - Wilate, July 24, 2007

Our STN: BL 125251/0

Octapharma Pharmazeutika Produktionsges. m.b.H
Attention: Barbara Rangetiner, Ph.D.
Oberlaaer Strasse 235
A-1100 Vienna

Dear Dr. Rangetiner:

This letter is in regard to your proposed proprietary names for Von Willebrand Factor Concentrate (Human), “WILATE” and “WILNATIV”, received on May 10, 2007.

We have considered your proposed proprietary names, "WILATE" and "WILNATIV" in consultation with CBER's Advertising and Promotional Labeling Branch (APLB) and conclude that under 21 CFR Part 201, the proposed proprietary name WILATE is acceptable and WILNATIV is not acceptable.

If you have any questions, please contact Mr. Franklin T. Stephenson, at (301) 827-3524.

Sincerely yours,

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 09/23/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English